Skip to main content

Table 2 Combination Indices (CI) for combination treatments in HS-SY-II and SYO-I

From: Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

HS-SY-II

SYO-I

 

Ridaforolimus

Vorinostat

 

Ridaforolimus

Vorinostat

Vorinostat

0.28 ± 0.06*

n/a

Vorinostat

0.63 ± 0.14*

n/a

Doxorubicin

0.56 ± 0.13

1.1 ± 0.06

Doxorubicin

0.50 ± 0.10

0.98 ± 0.11

Melphalan

0.51 ± 0.06

0.81 ± 0.08

Melphalan

0.59 ± 0.17

0.90 ± 0.02

  1. Data presented in Table 2 represent the mean ± SE from at least 3 independent experiments.
  2. *Indicates statistical significance of p < 0.05, when the CI for a given combination was compared between the two cell lines.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us